EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

The BEACON Study: A Phase 1b/2a, Dose Escalation Study of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of the c-Kit Mab Briquilimab in Adults with symptomatic Chronic Spontaneous Urticaria (CSU)

Saturday 01 Jun, 09:42 AM - 09:54 AM Valencia, Spain